Conclusion
allergic symptoms, allergic rhinoconjunctivitis, pain
ALLERGIC RHINOCONJUNCTIVITIS
This study first demonstrated that ICLIT could significantly relieve the allergic symptoms, improve the safety and compliance, and reduce the pain response among children with allergic rhinoconjunctivitis. In summary, ICLIT was a novel immunotherapy that could improve the clinical symptoms, save time and economic costs of children with allergic rhinoconjunctivitis.